The disproportional reduction in CRP levels in comparison with clinical measures of inflammation is a well-known phenomenon in RA patients treated with anti-IL-6R and, it has been suggested, in those treated with JAKi, due to the intracellular effects of JAKi on the IL-6 pathway. This evidence concerns the gene CRP and rheumatoid arthritis.